Increasing thiols for improving T cell immunotherapy
Ended Project Grant Awarded Last action
- Award ID
- R41CA271958
- Recipient
-
Lipo-Immuno TECH LLC UEI DH2EBEYDDJM9
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $394,167
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Place of performance
- South Carolina, USA
Award details come from USAspending.gov.
Description
- Abstract
- New strategies to improve adoptive cell therapy (act) protocols are emerging to enhance in vivo persistence of adoptively transferred tumor epitope-specific T cells and overcome tumor-induced immunosuppression. Our preliminary data suggests that there is a direct correlation between the long-lived central memory T cells (TCM) and their anti-oxidant capacity. Overexpression of thioredoxin-1 (TRX), a critical molecule that regulates cell- surface thiols (C-SH), increased TCM phenotype in T cells obtained from TCR transgenic mouse crossbred with TRX transgenic mouse, or engineering human T cells with a retroviral vector with TCR and TRX together. These preliminary observations led US to hypothesize that "the presence of TRX drives tumor-reactive T cells to a C-shhi phenotype, which results in increased persistence in the oxidative tumor microenvironment and improved tumor control." we propose to further strengthen the translational aspect of this strategy by determining if strategies to increase anti-oxidant capacity in presence of recombinant thioredoxin (RTRX) can reprogram tumor-infiltrating lymphocytes and improve TIL-mediated act. The experiments are planned under the following specific aims: 1) to determine if human tumor-derived tils could be EX vivo programmed with RTRX and exhibit enhanced anti- tumor phenotype, 2) to establish if RTRX tils are superior to conventional tils in controlling tumor growth in vivo. We believe that our studies are innovative and will uncover essential aspects that need to be considered when generating tumor-specific TCM/tscm cells for the act and enhance its wider use by decreasing the prohibitive costs.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $394,167 |
Quick answers
Who received award R41CA271958?
R41CA271958 was awarded to Lipo-Immuno TECH LLC by National Cancer Institute (National Institutes of Health) on September 13, 2022.
How much is award R41CA271958 worth?
$394,167 has been obligated on R41CA271958.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award